IRCT20200114046128N1已完成未知
A randomized, double-blind controlled trial study comparing the efficacy of granisetron versus lidocaine injection of trigger points in upper trapezius of patients with Myofascial Pain Syndrome referring to the AJA University Hospital
Artesh University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Being at least 18 years old
- •Neck or shoulder pain complaints for at least one month
- •At least one trigger point in the upper trapezius muscle
- •Non pregnant woman
- •No prior disease (severe cystic, spine, spinal canal stenosis)
- •No history of fibromyalgia or rheumatic diseases
- •No prior history of allergy to Granisetron or lidocaine
排除标准
- •No patient co-operation
- •No refer for follow up
- •Pain aggravation (unbearable for patient)
研究者
相似试验
招募中
Unknown
A double-blind, randomized controlled trial study on the preventive effect of cetylpyridinium chloride containing mouthwash on gingivitis during orthodontic treatmentgingivitisJPRN-UMIN000051198Ministry of Education, Culture, Sports, Science and Technology60
进行中（未招募）
1 期
A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to healthy infants at 2, 4 & 6 months of age followed by a booster dose at 12 months of ageThe vaccine is indicated for primary and booster vaccination of children against six infectious diseases: diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis caused by 3 types of poliovirus (type 1,2 and 3), and invasive infections caused by Haemophilus influenza type b.EUCTR2005-002578-31-CZSanofi Pasteur MSD S.N.C.800
进行中（未招募）
1 期
A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to healthy infants at 2, 4 & 6 months of age followed by a booster dose at 12 months of ageThe vaccine is indicated for primary and booster vaccination of children against six infectious diseases: diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis caused by 3 types of poliovirus (type 1,2 and 3), and invasive infections caused by Haemophilus influenza type b.EUCTR2005-002578-31-SKSanofi Pasteur MSD S.N.C.800
已完成
Unknown
A study to evaluate skin moisturization.CTRI/2023/05/052885Sami-Sabinsa Group Ltd30
已完成
Unknown
A study to evaluate skin moisturization.CTRI/2023/04/052081Abbott India Limited30